Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HLA-E drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HLA-E/B2M/Peptide Complex HEK293 co-expressed, high purity (>95%), sequence verified, endotoxin controlled. Ideal for binding and blocking assays. |
View HLA-E Products |
| Gene Delivery | HLA-E Lentivirus Full-length human HLA-E ORF for stable cell line generation (NK cell killing assays). |
View HLA-E Products |
| Benchmark Ab | Anti-HLA-E Recombinant Antibody Recombinant positive control derived from benchmark sequences for assay validation. |
View HLA-E Products |
| Validator | HLA-E siRNA Set Target-specific knockdown pool for specificity validation. |
View HLA-E Products |
| Related Target A | NKG2A Inhibitory receptor forming heterodimer with CD94; the primary functional partner of HLA-E. |
View NKG2A Products |
| Related Target B | NKG2C Activating receptor; critical counter-screening target to ensure selectivity. |
View NKG2C Products |
| Related Target C | B2M Beta-2-Microglobulin, essential chaperone required for HLA-E surface expression and stability. |
View B2M Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Stability & Peptide Loss | Pre-assembled HLA-E/B2M/Peptide heterotrimer, HEK293 expressed, preserving native-like conformation. |
| Off-Target HLA Cross-Reactivity | High-purity classical MHC (HLA-A/B/C) panel proteins available for counter-screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included as positive controls. |
| False Positives | Validated siRNA included for gene knockdown specificity checks. |
Live HLA-E R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HLA-E therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific immune cell engagers and NK-cell directed therapies. As first-generation NKG2A-blocking therapies (such as Monalizumab) reach advanced clinical phases, the next wave of R&D is targeting HLA-E directly to bypass the limitations of receptor-centric targeting and address HLA-E overexpression in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Innate Pharma, AstraZeneca | Head and Neck Cancer, Colorectal Cancer | Blockade Assay (Need stable, peptide-loaded HLA-E complex) |
| NK Cell Engagers (NKCEs) | Sanofi, Affimed | Hematological Malignancies, Solid Tumors | Binding Affinity & Selectivity (Need HLA-E vs HLA-A/B/C profiling) |
| TCR-T / CAR-NK Therapies | Academic Institutions, Biotech Startups | Refractory Solid Tumors | Target Cell Validation (Need HLA-E Lentivirus for stable expression) |